Marino Stram & Associates LLC Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Marino Stram & Associates LLC lifted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 34.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,842 shares of the company's stock after purchasing an additional 986 shares during the quarter. Eli Lilly and Company comprises about 0.7% of Marino Stram & Associates LLC's investment portfolio, making the stock its 23rd biggest position. Marino Stram & Associates LLC's holdings in Eli Lilly and Company were worth $3,173,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. PUREfi Wealth LLC grew its holdings in Eli Lilly and Company by 82.3% during the 1st quarter. PUREfi Wealth LLC now owns 1,285 shares of the company's stock valued at $1,061,000 after buying an additional 580 shares in the last quarter. Kingswood Wealth Advisors LLC boosted its position in shares of Eli Lilly and Company by 5.7% during the 1st quarter. Kingswood Wealth Advisors LLC now owns 9,254 shares of the company's stock valued at $7,591,000 after acquiring an additional 497 shares during the last quarter. Essex Savings Bank grew its holdings in shares of Eli Lilly and Company by 9.1% in the first quarter. Essex Savings Bank now owns 12,061 shares of the company's stock valued at $9,961,000 after purchasing an additional 1,007 shares in the last quarter. Puzo Michael J grew its holdings in shares of Eli Lilly and Company by 288.1% in the first quarter. Puzo Michael J now owns 2,542 shares of the company's stock valued at $2,099,000 after purchasing an additional 1,887 shares in the last quarter. Finally, Pegasus Asset Management Inc. increased its position in Eli Lilly and Company by 2.4% in the first quarter. Pegasus Asset Management Inc. now owns 5,228 shares of the company's stock worth $4,318,000 after purchasing an additional 124 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday, June 7th. Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. Finally, HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Trading Down 0.9%

LLY traded down $6.96 on Thursday, reaching $784.28. 2,441,727 shares of the company traded hands, compared to its average volume of 3,656,357. The company has a market cap of $743.29 billion, a P/E ratio of 63.81, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The firm has a fifty day simple moving average of $778.55 and a two-hundred day simple moving average of $801.58.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. During the same period last year, the business posted $2.58 earnings per share. The business's revenue was up 45.2% compared to the same quarter last year. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date was Friday, May 16th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.